Stay updated on Johnson & Johnson Press Releases
Sign up to get notified when there's something new on the Johnson & Johnson Press Releases page.
Latest updates to the Johnson & Johnson Press Releases page
- CheckyesterdayChange DetectedThe website has added significant updates including the approval applications for DARZALEX FASPRO® for high-risk smoldering multiple myeloma, new data on innovative treatments for rheumatic diseases, and the introduction of advanced joint reconstruction solutions, while removing previous results and details on TREMFYA® and other treatments.SummaryDifference100%
- Check9 days agoChange DetectedRecent updates highlight significant advancements in medical trials, including the completion of the OMNY-AF trial for the OMNYPULSE™ catheter and the EMPOWER CAD study focusing on coronary interventions in women, alongside the European Commission's approval of EDURANT® for younger pediatric patients with HIV-1.SummaryDifference100%
- Check16 days agoChange DetectedThe website now features 2,047 results and highlights significant advancements in neuropsychiatry and multiple myeloma treatments, including new long-term data on SPRAVATO® and the approval of a daratumumab-based regimen for newly diagnosed patients, while previous updates have been removed.SummaryDifference100%
- Check23 days agoChange DetectedNipocalimab has shown sustained disease control in adolescents with generalized myasthenia gravis in a Phase 2/3 study, marking a significant advancement in treatment options, while the company also reported a 5.2% sales growth in Q3 2024 and updated its full-year operational sales guidance.SummaryDifference100%
- Check31 days agoChange DetectedThe website has added significant updates including the U.S. FDA approval of TREMFYA® for ulcerative colitis, a new application for DARZALEX® in multiple myeloma, and the acquisition of V-Wave, while notable deletions include previous results for ERLEADA® and DARZALEX FASPRO®.SummaryDifference100%
- Check38 days agoChange DetectedJohnson & Johnson announced a significant investment of over $2 billion to build a new biologics manufacturing facility in North Carolina, aiming to enhance production capabilities and support the training of 500,000 health workers in Latin America and the Caribbean, while also achieving notable advancements in multiple myeloma treatments with new FDA filings and promising clinical study results.SummaryDifference100%
Stay in the know with updates to Johnson & Johnson Press Releases
Enter your email address, and we'll notify you when there's something new on the Johnson & Johnson Press Releases page.